INT49468

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 1995
Last Reported 2010
Negated 0
Speculated 2
Reported most in Body
Documents 28
Total Number 32
Disease Relevance 24.95
Pain Relevance 6.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
carotid body 2
pulmonary artery 2
bone marrow 1
glomus 1
chemoreceptor cells 1
Pah (Rattus norvegicus)
Pain Link Frequency Relevance Heat
fluoxetine 75 99.64 Very High Very High Very High
antagonist 199 99.52 Very High Very High Very High
Enkephalin 3 99.40 Very High Very High Very High
withdrawal 10 98.92 Very High Very High Very High
Somatosensory cortex 1 98.36 Very High Very High Very High
Spinal cord 1 95.92 Very High Very High Very High
sSRI 14 93.92 High High
opioid receptor 2 91.84 High High
ischemia 8 90.72 High High
agonist 15 90.68 High High
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 2699 100.00 Very High Very High Very High
Hypertrophy 510 100.00 Very High Very High Very High
Systemic Sclerosis 32 99.80 Very High Very High Very High
Hypoxia 526 98.84 Very High Very High Very High
Stroke 1 97.88 Very High Very High Very High
Reprotox - General 2 39 97.60 Very High Very High Very High
Disease 142 95.80 Very High Very High Very High
Death 35 94.64 High High
Increased Venous Pressure Under Development 96 92.56 High High
Recurrence 12 91.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The clinical evidence in support of the use of sildenafil, another phosphodiesterase type 5 inhibitor in PAH, will be also be reviewed.


Negative_regulation (inhibitor) of PAH associated with pulmonary hypertension
1) Confidence 0.55 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012445 Disease Relevance 0.73 Pain Relevance 0
Based on existing studies of sildenafil, a related selective phosphodiesterase type 5 inhibitor in PAH, and the findings of initial pilot studies, tadalafil appears to have excellent potential to provide therapeutic benefit in patients with pulmonary hypertension.
Negative_regulation (inhibitor) of PAH associated with pulmonary hypertension
2) Confidence 0.55 Published 2007 Journal Core Evidence Section Abstract Doc Link PMC3012445 Disease Relevance 0.79 Pain Relevance 0.03
Moreover, suppression of PAH activity with DMOG also increased the resting NO release, despite a weak effect comparing with that of the CPX.
Negative_regulation (suppression) of PAH
3) Confidence 0.51 Published 2007 Journal The Open Biochemistry Journal Section Body Doc Link PMC2570544 Disease Relevance 0.40 Pain Relevance 0
hydroxylation by suppressing prolyl hydroxylase (PAH) activity on the endogenous NO release measured electrochemically by microsensor inserted into the isolated carotid body superfused with bicarbonate-buffer were examined.
Negative_regulation (suppressing) of PAH in carotid body
4) Confidence 0.51 Published 2007 Journal The Open Biochemistry Journal Section Abstract Doc Link PMC2570544 Disease Relevance 0.30 Pain Relevance 0
Hence, the aims of the present study were to determine the effects of blockade of purinoceptors with suramin, or suppression of PAH activity with iron chelator CPX, and with the oxoglutarate analogue dimethyloxalylglycine (DMOG), on the endogenous NO release produced in some intraglomic structure, probably chemoreceptor cells and efferent fibers.


Spec (probably) Negative_regulation (suppression) of PAH in chemoreceptor cells
5) Confidence 0.51 Published 2007 Journal The Open Biochemistry Journal Section Body Doc Link PMC2570544 Disease Relevance 0.43 Pain Relevance 0.10
mg/kg/day) started 3 weeks after MCT injection completely reversed established PAH, normalizing pulmonary artery pressure and structure [22].
Negative_regulation (reversed) of PAH in pulmonary artery associated with pulmonary hypertension
6) Confidence 0.44 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 1.08 Pain Relevance 0.62
The reduced quantity of OATs translated into decreased renal uptake of p-aminohippurate (PAH; an organic anion), significantly decreased PAH renal excretion, and thus significantly lower PAH clearance.
Negative_regulation (decreased) of PAH
7) Confidence 0.41 Published 2008 Journal Crit Care Section Body Doc Link PMC2646335 Disease Relevance 0.66 Pain Relevance 0.28
In addition, oxoglutarate analogue suppresses PAH activity and increases endogenous HIF-1?
Negative_regulation (suppresses) of PAH
8) Confidence 0.37 Published 2007 Journal The Open Biochemistry Journal Section Body Doc Link PMC2570544 Disease Relevance 0.34 Pain Relevance 0.11
hydroxylation by suppressing PAH activity under normoxic conditions, closely mimic the effect of acute hypoxia on the NO production in the carotid body; (2) blockade of P2X and/or P2Y purinoceptors attenuated the effect of acute hypoxia on the NO production in the carotid body.
Negative_regulation (suppressing) of PAH in carotid body associated with hypoxia
9) Confidence 0.37 Published 2007 Journal The Open Biochemistry Journal Section Body Doc Link PMC2570544 Disease Relevance 0.61 Pain Relevance 0
In conclusion, iron chelation, which could suppress the PAH activity for HIF-1?
Negative_regulation (suppress) of PAH
10) Confidence 0.37 Published 2007 Journal The Open Biochemistry Journal Section Body Doc Link PMC2570544 Disease Relevance 0.76 Pain Relevance 0.08
However, little is known about pathophysiological features after reversal or attenuation of PAH; moreover, the long-term therapeutic effects of SERT inhibitors on PAH remain undetermined.
Negative_regulation (inhibitors) of PAH associated with pulmonary hypertension
11) Confidence 0.35 Published 2009 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 19473340 Disease Relevance 0.88 Pain Relevance 0.33
The purpose of this review is to evaluate the existing evidence for the use of tadalafil, a selective phosphodiesterase type 5 inhibitor, in PAH.


Negative_regulation (inhibitor) of PAH associated with pulmonary hypertension
12) Confidence 0.35 Published 2007 Journal Core Evidence Section Abstract Doc Link PMC3012445 Disease Relevance 0.96 Pain Relevance 0.04
After 12 weeks treatment, it was found that even through fluoxetine treatment resulted in complete reversal of PAH, PAH recurred after fluoxetine withdrawal.
Negative_regulation (reversal) of PAH associated with pulmonary hypertension, withdrawal and fluoxetine
13) Confidence 0.35 Published 2009 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 19473340 Disease Relevance 0.85 Pain Relevance 0.89
In PAH, flow velocity increases and decreases rapidly [18, 19] due to increased right ventricular stroke work and stiffness in the pulmonary artery leading to altered velocity profiles.
Negative_regulation (decreases) of PAH in pulmonary artery associated with pulmonary hypertension and stroke
14) Confidence 0.33 Published 2010 Journal Int J Cardiovasc Imaging Section Body Doc Link PMC2868165 Disease Relevance 0.96 Pain Relevance 0
level by iron chelators or PAH suppression has been shown to mimic the hypoxic effects on the potassium current, intracellular calcium level in the glomus cell and carotid chemoreceptor activity [7, 8, 11].
Negative_regulation (suppression) of PAH in glomus associated with hypoxia
15) Confidence 0.33 Published 2007 Journal The Open Biochemistry Journal Section Body Doc Link PMC2570544 Disease Relevance 0.61 Pain Relevance 0.03
A single injection of ONO-1301MS resulted in sustained activity for 3 weeks, and attenuated PAH, partly through its antiproliferative effect on vascular SMCs via inhibition of ERK phosphorylation [8].
Negative_regulation (attenuated) of PAH associated with pulmonary hypertension
16) Confidence 0.32 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.66 Pain Relevance 0.09
PAH and RV hypertrophy were reversed to near-normal levels.
Negative_regulation (reversed) of PAH associated with hypertrophy and pulmonary hypertension
17) Confidence 0.28 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 1.06 Pain Relevance 0.12
Also the inhalation of iloprost has been shown to reverse PAH and vascular structural remodeling in MCT-treated rats [9].

2.1.4.

Negative_regulation (reverse) of PAH associated with pulmonary hypertension
18) Confidence 0.28 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.66 Pain Relevance 0.06
Bone marrow-derived cells significantly attenuated PAH as assessed by reductions in RV pressure, RV weight, and percentage of muscularized pulmonary arterioles, compared to irradiated bone marrow-derived cells administered to MCTp-treated animals.
Negative_regulation (attenuated) of PAH in bone marrow associated with pulmonary hypertension
19) Confidence 0.28 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.64 Pain Relevance 0
Simvastatin attenuated MCT-induced pulmonary vascular remodeling, PAH, and RV hypertrophy in rats [36].
Negative_regulation (attenuated) of PAH associated with hypertrophy and pulmonary hypertension
20) Confidence 0.28 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 1.58 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox